References
- World Health Organization. GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012: Fact Sheet 2012. Lyon France 2012 http://globocan.iarc.fr/old/FactSheets/cancers/lung-new.asp. Accessed October 1, 2015
- Canadian Cancer Society. Lung cancer statistics 2015. Toronto, Ontario, Canada 2015 http://www.cancer.ca/en/cancer-information/cancer-type/lung/statistics/?region=on. Accessed October 1, 2015
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.6: Cancer of the Lung and Bronchus (Invasive): age-adjusted SEER Incidence Rates by Year, Race and Sex 2012. Bethesda, MD, USA 2012 http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.06.html. Accessed October 1, 2015
- Penrod JR, Korytowsky B, Petrilla A, et al. Survival of US medicare patients with advanced Non-Small Cell Lung Cancer (NSCLC) by Line of Therapy (abstract 6582). J Clin Oncol 2014;32 S5
- Public Health Agency of Canada. The prevalence of chronic pain and pain-related interference in the Canadian population from 1994 to 1998. 2014. Ottawa, Ontario, Canada 2014 http://www.phac-aspc.gc.ca/publicat/hpcdp-pspmc/31-4/ar-04-eng.php. Accessed June 30, 2015
- Leighl N. Treatment paradigms for patients with metastatic non-small-cell lung cancer: first-, second-, and third-line. Curr Oncol 2012;19(1 Suppl):S52–S58
- National Comprehensive Care Network (NCCN). Guidelines for Non-small cell lung cancer v 7.2015. 2015. Fort Washington, PA, USA http://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf. Accessed October 1, 2015
- Peterson P, Park K, Fossella F, et al. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007;2:S851
- Scagliotti G, Hanna N, Fossella F, et al. The differential efficacy of pemetrexed according to NSCLC histology: a review of two phase III studies. Oncologist 2009;14:253–63
- Rekhtman N, Paik PK, Arcila ME, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res 2012;18:1167–76
- Prince R, Atenafu E, Krzyzanowska M. Hospitalizations during systemic therapy for metastatic lung cancer: a systematic review of RealWorld vs clinical trial outcomes. JAMA Oncol. 2015;1(9):1333-1339. 2015;doi:10.1001/jamaoncol.2015.3440(online September 17, 2015):E1-E7.
- Kulkarni S, Vella E, Coakley N, et al. The use of systemic treatment in the maintenance of patients with non-small cell lung cancer. Toronto, ON: Cancer Care Ontario, 2015. Program in Evidence-based Care Evidence-based Series No.: 7–22. 2015
- Goffin J, Lacchetti C, Ellis PM, et al. First-line systemic chemotherapy in the treatment of advanced non-small cell lung cancer: a systematic review. J Thorac Oncol 2010;5:260–74
- Masters GA, Temin S, Azzoli CG, et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol 2015;33:3488–515
- Leighl NB, Rekhtman N, Biermann WA, et al. Molecular testing for selection of patients with lung cancer for epidermal growth factor receptor and anaplastic lymphoma kinase tyrosine kinase inhibitors: American Society of Clinical Oncology endorsement of the College of American Pathologists/International Association for the study of lung cancer/association for molecular pathology guideline. J Clin Oncol 2014;32:3673–9
- Besse B, Adjei A, Baas P, et al. 2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease. Ann Oncol 2014;25:1475–84
- Shepherd FA, Rodrigues PJ, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005;353:123–32
- Mandelblatt J, Fryback D, Weinstein M, et al. Assessing the effectiveness of health interventions. In: Gold M, Siegel J, Russell L, et al, eds. New York: Oxford University Press, 1996
- Latimer N. NICE DSU Technical Support Document 14: survival analysis for economic evaluations alongside clinical trials - Extrapolation with patient level data. 2011 National Institute for Health and Clinical Excellence (NICE) Decision Support Unit: Sheffield, UK available at: http://www.nicedsu.org.uk/NICE%20DSU%20TSD%20Survival%20analysis.updated%20March%202013.v2.pdf
- Latimer N. Survival analysis for economic evaluations alongside clinical trials—Extrapolation with patient-level data: inconsistencies, limitations, and a practical guide. MDM 2013;33:743–54.
- Royston P, Parmar M. Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175–97
- Coyle D, Coyle K. The inherent bias from using partitioned survival models in economic evaluation. Value Health 2014;17:A194
- Beca J, Hoch J. Exlporing the impact of structural uncertainty in partitioned survvial models for oncology. Value Health 2014;17:A205–6
- Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373:123–35
- Grambsch T, Therneau T. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 1993;81:515–26
- Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N, Chow L, Vokes E, Felip E, et al Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer N Engl J Med 2015; 373(17):1627-1639
- Chandra A, Vanderpuye-Orgle J, Summers N, et al. Indirect treatment comparison of relative efficacy and safety of nivolumab versus relevant comparator treatments among advanced non-small cell lung cancer patients of squamous cell receiving second-line or higher therapy. Los Angeles, CA: Precision Health Economics, 2015
- Garassino M, Martelli O, Broggini M, et al. Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. Lancet Oncol 2013;14:981–8
- Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the economic evaluation of health technologies, 3rd edn. Ottawa, Ontario: CADTH; 2006. https://www.cadth.ca/media/pdf/186_EconomicGuidelines_e.pdf. Accesed October 1, 2015
- Canadian Agency for Drugs and Technologies in Health (CADTH). Addendum to the Canadian Agency for Drugs and Technologies in health guidelines for the economic evaluation of health technologies: specific guidance for oncology products. Ottawa, Ontario: CADTH; 2009. https://www.cadth.ca/sites/default/files/pdf/H0405_Guidance_for_Oncology_Prodcuts_gr_e.pdf. Accessed October 1, 2015
- Statistics Canada. Consumer Price Index, health and personal care, by province (monthly). Government of Canada, 2015. Ottawa, Ontario, Canada http://www.statcan.gc.ca/tables-tableaux/sum-som/l01/cst01/cpis13a-eng.htm. Accessed June 30, 2015
- Ontario Ministry of Health and Long-Term Care. Schedule of benefits for physician services under the Health Insurance Act 2015. Toronto, Ontario, Canada 2015 http://www.health.gov.on.ca/english/providers/program/ohip/sob/physserv/physserv_mn.html. Accessed June 30, 2015
- Walker H, Anderson M, Farahati F, et al. Resource use and costs of end-of-Life/palliative care: Ontario adult cancer patients dying during 2002 and 2003. J Palliat Care 2011;27:79–88
- National Institute for Health and Care Excellence (NICE). Lung cancer (non-small cell, second line) – erlotinib and gefitinib (revision of TA162 and TA175) (ID620) Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed following prior chemotherapy (Review of TA162 and TA175): appraisal consultation document 2015. London, United Kingdom 2015 https://www.nice.org.uk/guidance/GID-TAG347/documents/erlotinib-and-gefitinib-for-treating-nonsmallcell-lung-cancer-that-has-progressed-following-prior-chemotherapy-review-of-ta162-and-ta175-appraisal-consultation-document. Accessed October 1, 2015
- University Health Network (UHN). Pharmacy Department (personal communication) Toronto, Ontario, Canada: Pharmacy Department, 2015
- McGill Health Sciences Centre. Pharmacy Department (personal communication) Montreal, Ontario, Canada: Pharmacy Department, 2015
- Dranitsaris G, Evans WK, Milliken D, et al. The impact of practice guidelines and funding policies on the use of new drugs in advanced non-small cell lung cancer. J Eval Clin Pract 2005;11:350–6
- Dranitsaris G, Cottrell W, Evans WK. Cost-effectiveness of chemotherapy for nonsmall-cell lung cancer. Curr Opin Oncol 2002;14:375–83
- Dranitsaris G, Beegle N, Ravelo A, et al. Evaluating the impact of bevacizumab maintenance therapy on overall survival in advanced non-small-cell lung cancer. Clin Lung Cancer 2013;14:120–7
- Solem C, Penrod J, Lees M, et al. Resource Utilization Among Advanced Squamous and non-Squamous non-Small Cell Lung Cancer Patients Receiving Second-Line Treatment in France, Germany, Italy, and Spain: Results of A Retrospective Medical Chart Review 2015. http://www.europeancancercongress.org/Scientific-Programme/Abstract-search#">http://www.europeancancercongress.org/Scientific-Programme/Abstract-search#http://www.poster-submission.com/ecc2015/visitors/carousel. 2015 Volume 18, Issue 7, Page A450 Accessed October 1, 2015
- Gettinger S, Horn L, Gandhi L, et al. Overall survival and long-term safety of nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2015;33:2004–12
- Rizvi N, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257–65
- Canadian Agency for Drugs and Technologies in Health (CADTH). pan-Canadian oncology drug review: final economic guidance report (Pemetrexed (Alimta) for non-squamous non-small cell lung cancer). 2013. Ottawa, Ontario, Canada https://www.cadth.ca/sites/default/files/pcodr/pcodr-alimta-ns-nsclc-fn-egr.pdf. Accessed October 1, 2015
- CADTH. pCODR final economic guidance report: crizotinib for advanced non-small cell lung cancer. 2013 Ottawa, Ontario, Canada
- CADTH. pCODR expert review committee final recommendation: ipilimumab for melanoma. 2012 Ottawa, Ontario, Canada
- Canadian Agency for Drugs and Technologies in Health (CADTH). pan-Canadian oncology drug review: final economic guidance report (Ipilimumab (Yervoy) for Advanced Melanoma). 2012. Ottawa, Ontario, Canada https://www.cadth.ca/sites/default/files/pcodr/pcodr-yervoy-adv-mel-fn-egr.pdf. Accessed October 1, 2015
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: table 15.30 cancer of the lung and bronchus (invasive): percent distribution and counts by histology among histologically confirmed cases, 2008-2012, females by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.30.html. Accessed October 1, 2015
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.29: cancer of the lung and bronchus (Invasive) - Percent distribution and counts by histology among histologically confirmed cases, 2008-2012; males by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.29.html. Accessed October 1, 2015
- National Cancer Institute. Surveillance, Epidemiology, and End Results (SEER) Program: Table 15.28: Cancer of the lung and bronchus (Invasive) - Percent distribution and counts by histology among histologically confirmed cases, 2008-2012; both sexes by race. 2012. Bethesda, MD, USA http://seer.cancer.gov/archive/csr/1975_2011/browse_csr.php?sectionSEL=15&pageSEL=sect_15_table.28.html. Accessed October 1, 2015